Analysis of the Microenvironment of Lung Cancer and Exploration of the Mechanism of Resistance to Immunotherapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Lung cancer is a highly heterogeneous disease. Cancer cells and cells within the tumor microenvironment together determine disease progression, as well as response to or escape from treatment. Tumor ecosystems are comprised of cancer cells, infiltrating immune cells, stromal cells, and other cell types together with noncellular tissue components, which interact and collectively determine disease progression as well as response to therapy. It is well known that cancer patients elicit very individualized responses to different treatments, demanding better characterization of the whole tumor ecosystem beyond currently applied clinical typing of somatic mutations in cancer cells.
Immune checkpoint blockers (ICBs) have revolutionized the management of patients with lung cancer. Blocking the interaction between the programmed cell death protein 1 (PD-1) receptor and its primary ligand (PD-L1) has demonstrated remarkable anticancer activity, and anti-PD-1/PD-L1 drugs have been approved both as single agents or in combination with cytotoxic chemotherapy. However, most patients receiving anti-PD-1/PD-L1 monoclonal antibodies do not derive benefit. Hence, there is a crucial need to identify reliable predictive biomarkers of the response to anti-PD-1/PD-L1 agents to develop precision medicine for NSCLC immunotherapy as well as to identify novel mechanisms underlying resistance to ICBs.
To map the cell type-specific landscape of cancer cells and their tumor microenvironment in lung cancer, the investigators plan to conduct a multiomics analysis（such as, Genomics, proteomics, single cell RNA sequencing, space transcriptomics）of tumor tissue and blood, aiming at analyzing tumor heterogeneity, mapping the microenvironment map of lung cancer and exploring the mechanism of sensitivity and resistance to anti-PD1/PD-L1 antibodies.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Kai Wang, PhD
- Phone Number: 13957158572
- Email: doctorhuxi@163.com
Study Contact Backup
- Name: Jiangnan Zhao, PhD
- Phone Number: 18267098035
- Email: zjn911016@126.com
Study Locations
-
-
Zhejiang
-
Yiwu, Zhejiang, China, 310000
- Recruiting
- the Fourth Affiliated Hospital of Zhejiang University
-
Contact:
- Kai Wang, PhD
- Phone Number: 13957158572
- Email: doctorhuxi@163.com
-
Contact:
- Jiangnan Zhao, PhD
- Phone Number: 18267098035
- Email: zjn911016@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Histopathology or hemology diagnostics of lung cancer
- Patients have never received any antineoplastic therapy
Exclusion Criteria:
- Within 5 years or at the same time, there are other active malignancies
- Currently participating in interventional clinical research treatment, or received other research drugs or used research devices within 4 weeks before the first administration
- Active autoimmune diseases requiring systemic treatment (such as the use of disease relieving drugs, glucocorticoids or immunosuppressants) occurred within 2 years before the first administration
- The study was receiving systemic glucocorticoid treatment (excluding local glucocorticoids by nasal spray, inhalation or other means) or any other form of immunosuppressive therapy within 7 days before the first administration; Note: It is allowed to use glucocorticoid with physiological dose (prednisone ≤ 10mg/day or equivalent)
- Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Other
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
objective response rate
Time Frame: three years
|
Refers to the proportion of patients whose tumor shrinkage reaches a certain amount and remains for a certain period of time, including CR + PR cases
|
three years
|
|
Major Pathologic Response
Time Frame: three-four months
|
<10% viable tumor in resected lung and lymph nodes
|
three-four months
|
|
progression-free survival
Time Frame: three years
|
Patients with oncological diseases have a period of time from the start of treatment to the observation of disease progression or death due to any cause
|
three years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Kai Wang, PhD, the Fourth Affiliated Hospital of Zhejiang University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- K2022179
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.